Alexion finally has a buyer – and it's AstraZeneca with $39bn on the table

Retrieved on: 2020-12-13 22:07:30

Tags for this article:

Life Sciences

Health sciences

Companies

Orphan drugs

Alexion Pharmaceuticals

Eculizumab

Biotechnology

Biosimilar

Atypical hemolytic uremic syndrome

Click the tags to see associated articles and topics

Alexion finally has a buyer – and it's AstraZeneca with $39bn on the table. View article details on hiswai:

Excerpt

Alexion has routinely featured among lists of top <b>biopharma</b> takeover prospects in the last couple of years, and that was a good call – AstraZeneca has ...

Article found on: pharmaphorum.com

View Original Article